遗传性额颞叶痴呆血清神经丝轻链的纵向多中心队列研究
本研究基于GENFI多中心队列,纳入59例症状性突变携带者、149例症状前携带者和127例非携带者,纵向检测血清NfL。结果发现症状性携带者基线NfL升高,症状前携带者中转为症状者NfL随访期间上升,且NfL变化率与MMSE下降及灰质萎缩率相关。
要点
- 症状性突变携带者血清NfL基线中位数52 pg/mL,显著高于症状前携带者9 pg/mL和非携带者8 pg/mL。
- 症状前携带者中转为症状者基线NfL为19 pg/mL,高于未转化携带者的8 pg/mL。
核心结论
- 血清NfL可作为遗传性额颞叶痴呆的疾病进展生物标志物,纵向监测有助于识别接近症状发作的突变携带者并反映脑萎缩速率。
研究设计与样本
- 研究为纵向多中心队列研究,纳入GENFI中来自欧洲和加拿大的14个中心的参与者,包括59例症状性突变携带者、149例症状前携带者和127例非携带者。
临床怎么用
- 在遗传性额颞叶痴呆的临床随访中,可考虑纵向监测血清NfL以辅助判断症状前携带者接近发病及评估疾病进展速度。
局限性
- 研究未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neurofilament light chain (NfL) is a promising blood biomarker in genetic frontotemporal dementia, with elevated concentrations in symptomatic carriers of mutations in GRN, C9orf72, and MAPT. A better understanding of NfL dynamics is essential for upcoming therapeutic trials. We aimed to study longitudinal NfL trajectories in people with presymptomatic and symptomatic genetic frontotemporal dementia. METHODS: We recruited participants from 14 centres collaborating in the Genetic Frontotemporal Dementia Initiative (GENFI), which is a multicentre cohort study of families with genetic frontotemporal dementia done across Europe and Canada. Eligible participants (aged ≥18 years) either had frontotemporal dementia due to a pathogenic mutation in GRN, C9orf72, or MAPT (symptomatic mutation carriers) or were healthy at-risk first-degree relatives (either presymptomatic mutation carriers or non-carriers), and had at least two serum samples with a time interval of 6 months or more. Participants were excluded if they had neurological comorbidities that were likely to affect NfL, including cerebrovascular events. We measured NfL longitudinally in serum samples collected between June 8, 2012, and Dec 8, 2017, through follow-up visits annually or every 2 years, which also included MRI and neuropsychological assessments. Using mixed-effects models, we analysed NfL changes over time and correlated them with longitudinal imaging and clinical parameters, controlling for age, sex, and study site. The primary outcome was the course of NfL over time in the various stages of genetic frontotemporal dementia. FINDINGS: We included 59 symptomatic carriers and 149 presymptomatic carriers of a mutation in GRN, C9orf72, or MAPT, and 127 non-carriers. Nine presymptomatic carriers became symptomatic during follow-up (so-called converters). Baseline NfL was elevated in symptomatic carriers (median 52 pg/mL [IQR 24-69]) compared with presymptomatic carriers (9 pg/mL [6-13]; p<0·0001) and non-carriers (8 pg/mL [6-11]; p<0·0001), and was higher in converters than in non-converting carriers (19 pg/mL [17-28] vs 8 pg/mL [6-11]; p=0·0007; adjusted for age). During follow-up, NfL increased in converters (b=0·097 [SE 0·018]; p<0·0001). In symptomatic mutation carriers overall, NfL did not change during follow-up (b=0·017 [SE 0·010]; p=0·101) and remained elevated. Rates of NfL change over time were associated with rate of decline in Mini Mental State Examination (b=-94·7 [SE 33·9]; p=0·003) and atrophy rate in several grey matter regions, but not with change in Frontotemporal Lobar Degeneration-Clinical Dementia Rating scale score (b=-3·46 [SE 46·3]; p=0·941). INTERPRETATION: Our findings show the value of blood NfL as a disease progression biomarker in genetic frontotemporal dementia and suggest that longitudinal NfL measurements could identify mutation carriers approaching symptom onset and capture rates of brain atrophy. The characterisation of NfL over the course of disease provides valuable information for its use as a treatment effect marker. FUNDING: ZonMw and the Bluefield project.
引用
- van der Ende EL, Meeter LH, Poos JM, et al. Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurol. 2019. PMID: 31701893. doi:10.1016/S1474-4422(19)30354-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。